Q2 2024 EPS Estimates for Compass Therapeutics, Inc. (NASDAQ:CMPX) Increased by Analyst

Compass Therapeutics, Inc. (NASDAQ:CMPXFree Report) – Stock analysts at HC Wainwright raised their Q2 2024 earnings per share estimates for Compass Therapeutics in a report released on Tuesday, May 14th. HC Wainwright analyst J. Pantginis now forecasts that the company will earn ($0.10) per share for the quarter, up from their previous estimate of ($0.11). HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Compass Therapeutics’ current full-year earnings is ($0.48) per share. HC Wainwright also issued estimates for Compass Therapeutics’ Q3 2024 earnings at ($0.11) EPS, Q4 2024 earnings at ($0.12) EPS, FY2024 earnings at ($0.41) EPS and FY2025 earnings at ($0.35) EPS.

Compass Therapeutics (NASDAQ:CMPXGet Free Report) last posted its earnings results on Thursday, March 21st. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.02).

Separately, Wedbush restated an “outperform” rating and issued a $8.00 price target on shares of Compass Therapeutics in a research note on Friday, March 22nd.

Get Our Latest Analysis on CMPX

Compass Therapeutics Stock Down 4.6 %

Shares of NASDAQ:CMPX opened at $1.54 on Thursday. The company’s 50-day moving average price is $1.76 and its 200 day moving average price is $1.68. The company has a market cap of $211.89 million, a PE ratio of -4.28 and a beta of 0.92. Compass Therapeutics has a fifty-two week low of $1.15 and a fifty-two week high of $3.62.

Institutional Investors Weigh In On Compass Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. SG Americas Securities LLC grew its position in Compass Therapeutics by 22.7% in the 4th quarter. SG Americas Securities LLC now owns 47,624 shares of the company’s stock valued at $74,000 after buying an additional 8,817 shares in the last quarter. Simplicity Wealth LLC acquired a new stake in shares of Compass Therapeutics in the 1st quarter worth approximately $80,000. Bleakley Financial Group LLC bought a new position in shares of Compass Therapeutics in the first quarter valued at approximately $80,000. Pale Fire Capital SE acquired a new position in shares of Compass Therapeutics during the third quarter valued at approximately $89,000. Finally, B. Riley Wealth Advisors Inc. raised its holdings in Compass Therapeutics by 235.2% during the third quarter. B. Riley Wealth Advisors Inc. now owns 50,000 shares of the company’s stock worth $98,000 after purchasing an additional 35,082 shares in the last quarter. 68.43% of the stock is currently owned by institutional investors.

About Compass Therapeutics

(Get Free Report)

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.

Featured Stories

Earnings History and Estimates for Compass Therapeutics (NASDAQ:CMPX)

Receive News & Ratings for Compass Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compass Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.